Immunovant, Inc.
IMVT · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $361 | $213 | $160 | $102 |
| G&A Expenses | $77 | $57 | $48 | $54 |
| SG&A Expenses | $77 | $57 | $48 | $54 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $438 | $270 | $208 | $156 |
| Operating Income | -$438 | -$270 | -$208 | -$156 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $25 | $11 | -$3 | -$1 |
| Pre-Tax Income | -$413 | -$259 | -$211 | -$157 |
| Tax Expense | $1 | $1 | $0 | -$0 |
| Net Income | -$414 | -$259 | -$211 | -$157 |
| % Margin | – | – | – | – |
| EPS | -2.73 | -1.88 | -1.71 | -1.43 |
| % Growth | -45.2% | -9.9% | -19.6% | – |
| EPS Diluted | -2.73 | -1.88 | -1.71 | -1.43 |
| Weighted Avg Shares Out | 152 | 138 | 123 | 110 |
| Weighted Avg Shares Out Dil | 152 | 138 | 123 | 110 |
| Supplemental Information | – | – | – | – |
| Interest Income | $25 | $25 | $8 | – |
| Interest Expense | $0 | $0 | $12 | – |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$438 | -$270 | -$208 | -$156 |
| % Margin | – | – | – | – |